Premium
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design
Author(s) -
Vishweshwaraiah Yashavantha L.,
Hnath Brianna,
Rackley Brendan,
Wang Jian,
Gontu Abhinay,
Chandler Morgan,
Afonin Kirill A.,
Kuchipudi Suresh V.,
Christensen Neil,
Yennawar Neela H.,
Dokholyan Nikolay V.
Publication year - 2022
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202206055
Subject(s) - epitope , virology , computational biology , linear epitope , biology , epitope mapping , antibody , heterologous , microbiology and biotechnology , genetics , gene
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) surface spike glycoprotein—a major antibody target—is critical for virus entry via engagement of human angiotensin‐converting enzyme 2 (ACE2) receptor. Despite successes with existing vaccines and therapies that primarily target the receptor binding domain (RBD) of the spike protein, the susceptibility of RBD to mutations provides escape routes for the SARS‐CoV‐2 from neutralizing antibodies. On the other hand, structural conservation in the spike protein can be targeted to reduce escape mutations and achieve broad protection. Here, candidate stable immunogens are designed that mimic surface features of selected conserved regions of spike protein through “epitope grafting,” in which the target epitope topology is presented on diverse heterologous scaffolds that can structurally accommodate the spike epitopes. Structural characterization of the epitope‐scaffolds showed stark agreement with computational models and target epitopes. The sera from mice immunized with engineered designs display epitope‐scaffolds and spike binding activity. The utility of the designed epitope‐scaffolds in diagnostic applications is also demonstrated. Taken all together, this study provides an important methodology for targeting the conserved, non‐RBD structural motifs of spike protein for SARS‐CoV‐2 epitope vaccine design and demonstrates the potential utility of “epitope grafting” in rational vaccine design.